% (n) | |
N° of DDIs | 427 |
N° DDI/patient, median (range) | 1 (1–6) |
N° DDI/patient, mean±SD | 1.6±1.0 |
Common DDIs by ATC: | |
A02 (drugs for acid related disorders) | 27.2% (116) |
N05 (psycholeptics) | 12.9% (55) |
C10 (lipid modifying agents) | 11.5% (49) |
C09 (agents acting on the renin-angiotensin system) | 9.8% (42) |
C08 (calcium channel blockers) | 7.7% (33) |
DDI by concomitant drug (five most frequent) | |
Omeprazole | 22.3% (95) |
Amlodipine | 6.8% (29) |
Atorvastatin | 5.6% (24) |
Lorazepam | 3.3% (14) |
Alprazolam | 3.0% (13) |
Main enzymes and drug transporters involved (five most frequent) | N=486 |
Indeterminate | 25.9% (126) |
P-gp | 20.0% (97) |
CYP3A4 | 19.8% (96) |
OATP1B1 | 8.8% (43) |
BCRP | 8.2% (40) |
Strength of DDI (%) | |
Potential interaction | 82.7% (353) |
Potential weak interaction | 12.2% (52) |
Contraindicated | 5.1% (22) |
Concomitant drug pharmacokinetic effect on DAAs | |
No effect | 67.3% (287) |
Decreased exposure | 17.3% (74) |
Indeterminate | 8.4% (36) |
Increased exposure | 7.0% (30) |
DAA pharmacokinetic effect on concomitant drug | |
Increased exposure | 66.3% (283) |
No effect | 24.1% (103) |
Decreased exposure | 7.0% (30) |
Indeterminate | 2.6% (11) |
Therapeutic recommendation on concomitant drug | |
No dose alteration is required | 45.9% (196) |
Temporary withdrawal during antiviral treatment | 25.6% (109) |
Administration schedule adjustment | 16.6% (71) |
Dose adjustment | 10.3% (44) |
Therapeutic alternative prescription | 1.6% (7) |
ATC, anatomical therapeutic classification; BCRP, breast cancer resistant protein; CYP3A4, cytochromo P450 3A4;DAA, direct-acting antiviral; DDI, drug–drug interactions; OATP1B1, organic-anion-transporting polypeptide 1B1; P-gp, P-glycoprotein.